Location History:
- Downers Grove, IL (US) (2021)
- Chicago, IL (US) (2022)
Company Filing History:
Years Active: 2021-2022
Title: Innovations by Joshua Drews in Cancer Research
Introduction
Joshua Drews is an accomplished inventor based in Chicago, IL (US). He has made significant contributions to the field of cancer research through his innovative patents. With a total of 2 patents, his work focuses on improving the detection and analysis of cellular pathways in cancer specimens.
Latest Patents
One of his latest patents is titled "Systems and methods for detecting cellular pathway dysregulation in cancer specimens." This invention discloses systems, methods, and compositions that are useful for determining cellular pathway disruption. It utilizes RNA expression level information to assist in identifying genetic variants that alter pathway activity. This can correlate these variants with disease state and progression, ultimately helping to identify effective therapeutics.
Another notable patent is "Systems and methods for automating RNA expression calls in a cancer prediction pipeline." This patent provides systems and methods for performing quality control analysis on batch datasets derived from RNA sequencing. The method includes obtaining a batch dataset, determining a cohort-matched reference batch, and performing global batch quality control tests. It ensures that samples failing quality control are either removed or flagged for manual inspection.
Career Highlights
Joshua Drews has worked with notable companies in the field, including Tempus Labs, Inc. and Tempus AI, Inc. His experience in these organizations has allowed him to contribute to advancements in cancer diagnostics and treatment.
Collaborations
Throughout his career, Joshua has collaborated with professionals such as Joshua S. K. Bell and Catherine Igartua. These collaborations have further enriched his work and expanded the impact of his innovations.
Conclusion
Joshua Drews is a prominent inventor whose work in cancer research has led to significant advancements in the detection and analysis of cellular pathways. His innovative patents reflect his commitment to improving cancer diagnostics and treatment options.